Tag: Protocol

Posted on by — Leave a comment

Retatrutide 10mg Dosage Protocol

Preparation & Measurement Guide

Retatrutide 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Retatrutide 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Retatrutide 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
2-12mg once weekly

1. Preparation and Measurement

Retatrutide 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in phase 2 research. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2mg once weekly 0.4mL / 40 units
Weeks 5-8 4mg once weekly 0.8mL / 80 units
Weeks 9-12 8mg once weekly 1.6mL / 160 units*
Weeks 13+ 12mg once weekly 2.4mL / 240 units*

Vial estimate: One 10mg vial contains approximately 5 administrations at the first listed amount; later rows exceed one vial’s total content.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Retatrutide 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Retatrutide is an investigational triple receptor agonist studied in phase 2 trials. It is not an approved medicine, and later-stage research may use different designs or conclusions.

The table records a phase 2-style escalation for educational comparison. It is not a prescribing schedule or evidence that a laboratory vial is suitable for human use.

Primary Research and Regulatory References

  1. Retatrutide phase 2 obesity trial
  2. Retatrutide phase 2 diabetes trial
  3. Retatrutide phase 2 trial registry

Research Materials

Review Retatrutide 10mg Product Information

View Retatrutide 10mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Retatrutide 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Retatrutide 20mg Dosage Protocol

Preparation & Measurement Guide

Retatrutide 20mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Retatrutide 20mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Retatrutide 20mg
Preparation
2mL bacteriostatic water
Concentration
10mg/mL after preparation
Documented Convention
2-12mg once weekly

1. Preparation and Measurement

Retatrutide 20mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 10mg/mL. On a U-100 syringe, each unit contains 100mcg.

20mg / 2mL = 10mg/mL
1 U-100 unit = 0.01mL = 100mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in phase 2 research. Frequency: once weekly.

Period Documented amount Measurement
Weeks 1-4 2mg once weekly 0.2mL / 20 units
Weeks 5-8 4mg once weekly 0.4mL / 40 units
Weeks 9-12 8mg once weekly 0.8mL / 80 units
Weeks 13+ 12mg once weekly 1.2mL / 120 units*

Vial estimate: One 20mg vial contains approximately 10 administrations at the first listed amount or 1 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Retatrutide 20mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Retatrutide is an investigational triple receptor agonist studied in phase 2 trials. It is not an approved medicine, and later-stage research may use different designs or conclusions.

The table records a phase 2-style escalation for educational comparison. It is not a prescribing schedule or evidence that a laboratory vial is suitable for human use.

Primary Research and Regulatory References

  1. Retatrutide phase 2 obesity trial
  2. Retatrutide phase 2 diabetes trial
  3. Retatrutide phase 2 trial registry

Research Materials

Review Retatrutide 20mg Product Information

View Retatrutide 20mg
Browse Weight Management

← Back to Dosage Protocols

Research-use disclaimer: Retatrutide 20mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Kisspeptin 10mg Dosage Protocol

Preparation & Measurement Guide

Kisspeptin 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Kisspeptin 10mg vial.

Research use only
Educational comparator summary. This research material is not an approved drug product.
Vial Size
Kisspeptin 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
100-200mcg once daily

1. Preparation and Measurement

Kisspeptin 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 100mcg once daily 0.02mL / 2 units
Weeks 3-8 200mcg once daily 0.04mL / 4 units

Vial estimate: One 10mg vial contains approximately 100 administrations at the first listed amount or 50 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Kisspeptin 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Kisspeptin peptides have been studied in controlled human endocrine research involving gonadotropin release and reproductive signalling. Responses depend on the peptide form, route, population, and study design.

Kisspeptin research material is not an approved drug product. A circulated vial schedule should not be treated as equivalent to a clinical study protocol.

Primary Research and Regulatory References

  1. Kisspeptin-54 human endocrine study
  2. Kisspeptin reproductive-axis clinical study

Research Materials

Review Kisspeptin 10mg Product Information

View Kisspeptin 10mg
Browse All Peptides

← Back to Dosage Protocols

Research-use disclaimer: Kisspeptin 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

KLOW Blend 80mg Dosage Protocol

Preparation & Measurement Guide

KLOW Blend 80mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a KLOW Blend 80mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
10mg BPC-157 + 10mg TB-500 + 10mg KPV + 50mg GHK-CU
Preparation
2mL bacteriostatic water
Concentration
40mg/mL after preparation
Documented Convention
2-6mg total once daily

1. Preparation and Measurement

KLOW Blend 80mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 40mg/mL. On a U-100 syringe, each unit contains 400mcg.

80mg / 2mL = 40mg/mL
1 U-100 unit = 0.01mL = 400mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 2mg total once daily 0.05mL / 5 units
Weeks 3-4 4mg total once daily 0.1mL / 10 units
Weeks 5-8 6mg total once daily 0.15mL / 15 units

Vial estimate: One 80mg vial contains approximately 40 administrations at the first listed amount or 13 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • At 5 units: 250mcg BPC-157, 250mcg TB-500, 250mcg KPV, and 1.25mg GHK-CU.
  • At 10 units: 500mcg BPC-157, 500mcg TB-500, 500mcg KPV, and 2.5mg GHK-CU.
  • At 15 units: 750mcg BPC-157, 750mcg TB-500, 750mcg KPV, and 3.75mg GHK-CU.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • KLOW Blend 80mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

KLOW combines BPC-157, TB-500, KPV, and GHK-CU in a fixed ratio. The exact four-component blend has not been evaluated in controlled human trials.

Research on individual components cannot establish the combined material’s safety, efficacy, interactions, or optimal schedule. The table records a circulated total-mass convention only.

Primary Research and Regulatory References

  1. BPC-157 rat Achilles tendon study
  2. Thymosin beta-4 wound-healing research
  3. KPV intestinal inflammation study
  4. Copper peptide tissue-remodelling review

Research Materials

Review KLOW Blend 80mg Product Information

View KLOW Blend 80mg
Browse Peptide Blends

← Back to Dosage Protocols

Research-use disclaimer: KLOW Blend 80mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

KPV 10mg Dosage Protocol

Preparation & Measurement Guide

KPV 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a KPV 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
KPV 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
200-500mcg once daily

1. Preparation and Measurement

KPV 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Week 1 200mcg once daily 0.04mL / 4 units
Week 2 300mcg once daily 0.06mL / 6 units
Week 3 400mcg once daily 0.08mL / 8 units
Weeks 4-8 500mcg once daily 0.1mL / 10 units

Vial estimate: One 10mg vial contains approximately 50 administrations at the first listed amount or 20 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • KPV 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

KPV is an alpha-MSH-derived tripeptide studied mainly in cell and animal models involving intestinal transport and inflammatory signalling. These findings do not establish a human dose.

KPV is not an approved therapeutic drug. The staged table is a documented research convention only.

Primary Research and Regulatory References

  1. KPV intestinal inflammation study
  2. KPV transporter and intestinal research
  3. KPV experimental inflammation study

Research Materials

Review KPV 10mg Product Information

View KPV 10mg
Browse Recovery and Repair

← Back to Dosage Protocols

Research-use disclaimer: KPV 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Melanotan-2 10mg Dosage Protocol

Preparation & Measurement Guide

Melanotan-2 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Melanotan-2 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Melanotan-2 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
250-750mcg once daily

1. Preparation and Measurement

Melanotan-2 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 250mcg once daily 0.05mL / 5 units
Weeks 3-4 500mcg once daily 0.1mL / 10 units
Weeks 5-8 750mcg once daily 0.15mL / 15 units

Vial estimate: One 10mg vial contains approximately 40 administrations at the first listed amount or 13 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Melanotan-2 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Melanotan-II is an unapproved melanocortin analogue studied in early human experiments. Published case reports also describe clinically significant adverse effects associated with unregulated use.

No approved dosing standard exists for Melanotan-II. The table documents a circulated convention and does not establish safety.

Primary Research and Regulatory References

  1. Melanotan-II early human study
  2. Melanotan-II human response study
  3. Melanotan-II safety case report

Research Materials

Review Melanotan-2 10mg Product Information

View Melanotan-2 10mg
Browse All Peptides

← Back to Dosage Protocols

Research-use disclaimer: Melanotan-2 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

MOTS-C 10mg Dosage Protocol

Preparation & Measurement Guide

MOTS-C 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a MOTS-C 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
MOTS-C 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
200mcg-1mg once daily

1. Preparation and Measurement

MOTS-C 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 200mcg once daily 0.04mL / 4 units
Weeks 3-4 400mcg once daily 0.08mL / 8 units
Weeks 5-6 600mcg once daily 0.12mL / 12 units
Weeks 7-8 800mcg once daily 0.16mL / 16 units
Weeks 9-12 1mg once daily 0.2mL / 20 units

Vial estimate: One 10mg vial contains approximately 50 administrations at the first listed amount or 10 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • MOTS-C 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

MOTS-c is a mitochondrial-derived peptide studied in metabolic regulation, stress responses, and exercise-related signalling. Much of the evidence is preclinical, with limited observational human research.

MOTS-c is not an approved therapeutic drug, and no clinically validated human schedule has been established.

Primary Research and Regulatory References

  1. MOTS-c metabolic regulation review
  2. MOTS-c exercise and metabolic research
  3. MOTS-c human exercise-response study

Research Materials

Review MOTS-C 10mg Product Information

View MOTS-C 10mg
Browse Longevity and Cellular Research

← Back to Dosage Protocols

Research-use disclaimer: MOTS-C 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

IGF-1 LR3 1mg Dosage Protocol

Preparation & Measurement Guide

IGF-1 LR3 1mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a IGF-1 LR3 1mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
IGF-1 LR3 1mg
Preparation
1mL bacteriostatic water
Concentration
1mg/mL after preparation
Documented Convention
20-50mcg once daily

1. Preparation and Measurement

IGF-1 LR3 1mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 1mg/mL. On a U-100 syringe, each unit contains 10mcg.

1mg / 1mL = 1mg/mL
1 U-100 unit = 0.01mL = 10mcg

Preparation

  1. Draw 1mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated research protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 20mcg once daily 0.02mL / 2 units
Weeks 3-4 40mcg once daily 0.04mL / 4 units
Weeks 5-8 50mcg once daily 0.05mL / 5 units

Vial estimate: One 1mg vial contains approximately 50 administrations at the first listed amount or 20 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 1mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • IGF-1 LR3 1mg vial.
  • 1mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

IGF-1 LR3 is a modified IGF-1 analogue developed to alter protein binding and biological persistence. Most supporting work is preclinical or laboratory based and does not establish a clinically validated human dose.

IGF-1 LR3 is not an approved therapeutic drug. The table records a circulated research convention for comparison, not a safety or efficacy recommendation.

Primary Research and Regulatory References

  1. IGF-1 analogue binding and biological activity study
  2. Long R3 IGF-I metabolism study
  3. Long R3 IGF-I experimental response study

Research Materials

Review IGF-1 LR3 1mg Product Information

View IGF-1 LR3 1mg
Browse Growth Hormone Research

← Back to Dosage Protocols

Research-use disclaimer: IGF-1 LR3 1mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Ipamorelin 10mg Dosage Protocol

Preparation & Measurement Guide

Ipamorelin 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Ipamorelin 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Ipamorelin 10mg
Preparation
2mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
100-200mcg once daily

1. Preparation and Measurement

Ipamorelin 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 100mcg once daily 0.02mL / 2 units
Weeks 3-4 150mcg once daily 0.03mL / 3 units
Weeks 5-8 200mcg once daily 0.04mL / 4 units

Vial estimate: One 10mg vial contains approximately 100 administrations at the first listed amount or 50 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Ipamorelin 10mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Ipamorelin is a growth-hormone secretagogue studied in experimental pharmacology and early human research. The available literature does not establish a standard therapeutic protocol.

Ipamorelin is not an approved therapeutic drug. The staged schedule records a commonly circulated convention for comparison.

Primary Research and Regulatory References

  1. Ipamorelin growth-hormone secretagogue study
  2. Ipamorelin pharmacology study

Research Materials

Review Ipamorelin 10mg Product Information

View Ipamorelin 10mg
Browse Growth Hormone Research

← Back to Dosage Protocols

Research-use disclaimer: Ipamorelin 10mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

Ipamorelin 5mg Dosage Protocol

Preparation & Measurement Guide

Ipamorelin 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Ipamorelin 5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
Ipamorelin 5mg
Preparation
1mL bacteriostatic water
Concentration
5mg/mL after preparation
Documented Convention
100-200mcg once daily

1. Preparation and Measurement

Ipamorelin 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL
1 U-100 unit = 0.01mL = 50mcg

Preparation

  1. Draw 1mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period Documented amount Measurement
Weeks 1-2 100mcg once daily 0.02mL / 2 units
Weeks 3-4 150mcg once daily 0.03mL / 3 units
Weeks 5-8 200mcg once daily 0.04mL / 4 units

Vial estimate: One 5mg vial contains approximately 50 administrations at the first listed amount or 25 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 1mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • Ipamorelin 5mg vial.
  • 1mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Ipamorelin is a growth-hormone secretagogue studied in experimental pharmacology and early human research. The available literature does not establish a standard therapeutic protocol.

Ipamorelin is not an approved therapeutic drug. The staged schedule records a commonly circulated convention for comparison.

Primary Research and Regulatory References

  1. Ipamorelin growth-hormone secretagogue study
  2. Ipamorelin pharmacology study

Research Materials

Review Ipamorelin 5mg Product Information

View Ipamorelin 5mg
Browse Growth Hormone Research

← Back to Dosage Protocols

Research-use disclaimer: Ipamorelin 5mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

GHK-CU 50mg Dosage Protocol

Preparation & Measurement Guide

GHK-CU 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a GHK-CU 50mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
GHK-CU 50mg
Preparation
2mL bacteriostatic water
Concentration
25mg/mL after preparation
Documented Convention
1-2mg, five days weekly

1. Preparation and Measurement

GHK-CU 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL
1 U-100 unit = 0.01mL = 250mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated vial protocols. Frequency: five days per week.

Period Documented amount Measurement
Weeks 1-2 1mg once daily, five days per week 0.04mL / 4 units
Weeks 3-4 1.5mg once daily, five days per week 0.06mL / 6 units
Weeks 5-8 2mg once daily, five days per week 0.08mL / 8 units

Vial estimate: One 50mg vial contains approximately 50 administrations at the first listed amount or 25 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Some entries are very small measurements; account for the accuracy of the measuring device.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • GHK-CU 50mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

GHK-Cu has been studied in wound, tissue-remodelling, gene-expression, and skin research. Much of the literature uses topical, cell, or animal models rather than injectable human protocols.

GHK-Cu is not approved as an injectable therapeutic drug. The table records a circulated vial convention only.

Primary Research and Regulatory References

  1. Copper peptide tissue-remodelling review
  2. GHK-Cu gene-expression research
  3. Copper peptide wound-healing study

Research Materials

Review GHK-CU 50mg Product Information

View GHK-CU 50mg
Browse Recovery and Repair

← Back to Dosage Protocols

Research-use disclaimer: GHK-CU 50mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.

Posted on by — Leave a comment

GLOW Blend 50mg Dosage Protocol

Preparation & Measurement Guide

GLOW Blend 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a GLOW Blend 50mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.
Vial Size
5mg BPC-157 + 35mg GHK-CU + 10mg TB-500
Preparation
2mL bacteriostatic water
Concentration
25mg/mL after preparation
Documented Convention
2.5mg total once daily

1. Preparation and Measurement

GLOW Blend 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL
1 U-100 unit = 0.01mL = 250mcg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily for four weeks.

Period Documented amount Measurement
Weeks 1-4 2.5mg total once daily 0.1mL / 10 units

Vial estimate: One 50mg vial contains approximately 20 documented-size administrations at 2.5mg.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • At 10 units: 250mcg BPC-157, 1.75mg GHK-CU, and 500mcg TB-500.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • GLOW Blend 50mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

GLOW combines BPC-157, GHK-CU, and TB-500 in a fixed ratio. The exact three-component blend has not been evaluated in controlled human trials.

Research on individual components cannot establish the combined material’s safety, efficacy, interactions, or optimal schedule. The table records a circulated total-mass convention only.

Primary Research and Regulatory References

  1. BPC-157 rat Achilles tendon study
  2. Copper peptide tissue-remodelling review
  3. GHK-Cu gene-expression research
  4. Thymosin beta-4 wound-healing research

Research Materials

Review GLOW Blend 50mg Product Information

View GLOW Blend 50mg
Browse Peptide Blends

← Back to Dosage Protocols

Research-use disclaimer: GLOW Blend 50mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.